Reid L, Bakker-Arkema R, Black D
Parke-Davis Pharmaceutical Research, Eye Physicians of Cincinnati, Ann Arbor, Ohio, USA
J Cardiovasc Pharmacol Ther. 1998 Jan;3(1):71-76. doi: 10.1177/107424849800300109.
The effect of atorvastatin calcium (Lipitor, Parke-Davis, Morris Plains, NJ) on the crystalline lenses of hypercholesterolemic patients was evaluated and compared with that of lovastatin after 52 weeks of treatment to reduce cholesterol levels. METHODS AND RESULTS: Six hundred ninety-six atorvastatin-treated and 235 lovastatin-treated patients completed a large safety study that included an ophthalmologic examination. Efficacy was evaluated as mean percent change from baseline in low-density lipoprotein (LDL) cholesterol. Patients received atorvastatin, 10 or 20 mg, or lovastatin, 20 or 40 mg, once daily for either 36 or 52 weeks. Patients were evaluated by slit-lamp examination, and a standardized format was used to describe the findings. Best corrected visual acuity was measured using the Snellen chart. Patients treated with atorvastatin had significantly (P </=.05) greater decreases in LDL cholesterol than those treated with lovastatin (37% vs 29%). Although some patients in both groups experienced various lenticular opacities, none were considered unexpected. In addition, there were no significant (P </=.05) differences in the distribution of cortical opacities and spokes right eye (OD) and left eye (OS) and posterior subcapsular opacity (OS) between the atorvastatin and lovastatin groups. In general, the percent deterioration in best corrected visual acuity was similar in both groups. Overall, there were no clinically significant differences in the development of lenticular opacity between patients treated with atorvastatin and those treated with lovastatin. CONCLUSIONS: Treatment with atorvastatin, 10 or 20 mg, significantly reduced LDL-cholesterol (P <.05) and was not associated with an increased risk of lenticular opacity development compared with lovastatin, a widely prescribed compound in the same class of drugs.
评估阿托伐他汀钙（立普妥，帕罗西汀-戴维斯公司，新泽西州莫里斯平）对高胆固醇血症患者晶状体的影响，并在治疗52周降低胆固醇水平后与洛伐他汀的效果进行比较。
696例接受阿托伐他汀治疗和235例接受洛伐他汀治疗的患者完成了一项大型安全性研究，其中包括眼科检查。疗效评估为低密度脂蛋白（LDL）胆固醇相对于基线的平均变化百分比。患者接受10或20毫克阿托伐他汀或20或40毫克洛伐他汀，每日一次，持续36或52周。通过裂隙灯检查对患者进行评估，并使用标准化格式描述检查结果。使用斯内伦视力表测量最佳矫正视力。接受阿托伐他汀治疗的患者LDL胆固醇的降低幅度显著大于接受洛伐他汀治疗的患者（37%对29%，P≤0.05）。虽然两组中的一些患者出现了各种晶状体混浊，但均未被视为意外情况。此外，阿托伐他汀组和洛伐他汀组之间在皮质混浊、右眼（OD）和左眼（OS）的辐条以及后囊下混浊（OS）的分布上没有显著差异（P≤0.05）。总体而言，两组最佳矫正视力的恶化百分比相似。总体而言，接受阿托伐他汀治疗的患者和接受洛伐他汀治疗的患者在晶状体混浊的发生方面没有临床显著差异。
与同一类药物中广泛使用开的洛伐他汀相比，10或20毫克阿托伐他汀治疗可显著降低LDL胆固醇（P<0.05），且与晶状体混浊发生风险增加无关。
